Design 1st Engineers the Self-Organizing Lūp, Bringing Modern Innovation to the Everyday Charging Cable
April 16, 2024 08:00 ET
|
Design 1st
OTTAWA, April 16, 2024 (GLOBE NEWSWIRE) -- Design 1st, one of the most prolific full-service product design-engineering firms across North America, has helped design and develop the Lūp Cable, the...
Ongoing Point of Care Ultrasound Certification Academy Study Aims to Identify Top 25 POCUS Practice Domains
April 10, 2024 11:57 ET
|
Inteleos, Inc.
ROCKVILLE, Md., April 10, 2024 (GLOBE NEWSWIRE) -- Inteleos, a non-profit global healthcare certification organization, through its Point-of-Care Ultrasound (POCUS) Certification Academy (PCA),...
Thor Equities Group Chairman, Joe Sitt, Makes Guest Appearance on Bloomberg Markets to Discuss Inflation, Electric Vehicles, and More
April 09, 2024 15:41 ET
|
Thor Equities Group
New York, NY, April 09, 2024 (GLOBE NEWSWIRE) -- Joe Sitt, Chairman of leading global real estate firm, Thor Equities Group, spoke on Bloomberg Markets on April 9th to discuss Electreon, the leading...
Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
April 09, 2024 15:34 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...
Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
April 08, 2024 11:36 ET
|
Revolution Medicines, Inc.
Two original papers in Nature highlight the discovery and translational implications of RMC-7977, a RAS(ON) multi-selective tri-complex inhibitor that exhibits unprecedented anti-tumor activity in...
Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation as the Company Conducts Two Pivotal Studies for Revita in Obesity and Type 2 Diabetes
April 02, 2024 08:00 ET
|
Fractyl Health, Inc.
Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation
OMNIQ ANNOUNCES 2023 REVENUE OF $81.4 MILLION
April 01, 2024 17:11 ET
|
OMNIQ Corp.
SALT LAKE CITY, April 01, 2024 (GLOBE NEWSWIRE) -- OMNIQ Corp. (NASDAQ: OMQS) (“OMNIQ” or the “Company”), a provider of Artificial Intelligence (AI) and IoT–based solutions will release Full Year...
Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
April 01, 2024 07:00 ET
|
Fractyl Health, Inc.
Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Fractyl Health Receives FDA IDE Approval for the Revita® Remain-1 Pivotal Study of Weight Maintenance in Obesity after Discontinuation of GLP-1 Based Drugs
April 01, 2024 06:00 ET
|
Fractyl Health, Inc.
Fractyl Health Receives FDA IDE Approval for the Revita® Remain-1 Pivotal Study of Weight Maintenance in Obesity after Discontinuation of GLP-1 Based Drugs
Thor Equities Group and Vesper Holdings Launch Student Housing Joint Venture
March 20, 2024 14:38 ET
|
Thor Equities Group
New York, NY, March 20, 2024 (GLOBE NEWSWIRE) -- Thor Equities Group and Vesper Holdings, leaders in real estate development and investment, are pleased to announce the launch of a joint venture...